SCHEMBL2233115

SCHEMBL2233115

CCC(=O)N1CCN(c2ccc(Nc3ncnc4c(C(=O)Nc5c(Cl)c(OC)cc(OC)c5Cl)csc34)cc2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR3 P22607 10/20 0.48
FGFR2 P21802 6/20 0.48
FGFR1 P11362 6/20 0.48
FGFR4 P22455 5/20 0.48
BRAF P15056 4/20 0.48
SRC P12931 3/20 0.48
ALK Q9UM73 3/20 0.48
JAK2 O60674 2/20 0.48
ABL1 P00519 2/20 0.48
INSR P06213 2/20 0.48
LCK P06239 2/20 0.48
FYN P06241 2/20 0.48
YES1 P07947 2/20 0.48
LYN P07948 2/20 0.48
RET P07949 2/20 0.48
MET P08581 2/20 0.48
ROS1 P08922 2/20 0.48
KIT P10721 2/20 0.48
PDGFRA P16234 2/20 0.48
FLT1 P17948 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14125201 0.96 BRAF (0.45) FGFR3FGFR2FGFR1FGFR4BRAF
SCHEMBL2236404 0.92 FGFR3 (0.47) FGFR3FGFR2FGFR1FGFR4BRAF
SCHEMBL20895036 0.92 FGFR3 (0.48) FGFR3FGFR2FGFR1FGFR4BRAF
SCHEMBL2232217 0.91 FGFR3 (0.58) FGFR3FGFR2FGFR1FGFR4BRAF
SCHEMBL14125198 0.89 FGFR3 (0.45) FGFR3FGFR2FGFR1FGFR4BRAF
SCHEMBL2235550 0.89 FGFR3 (0.53) FGFR3FGFR2FGFR1FGFR4BRAF
SCHEMBL14137347 0.89 BRAF (0.42) FGFR3FGFR2FGFR1FGFR4BRAF
SCHEMBL2235698 0.88 FGFR3 (0.45) FGFR3FGFR2FGFR1FGFR4BRAF
SCHEMBL2234513 0.88 FGFR3 (0.49) FGFR3FGFR2FGFR1FGFR4BRAF
SCHEMBL2232776 0.88 FGFR1 (0.45) FGFR3FGFR2FGFR1FGFR4BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3141552-B1 THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE HANMI PHARM IND CO LTD (KR) 2019-04-17 EP claimed
US-10112954-B2 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase HANMI PHARM. CO., LTD. (KR) 2018-10-30 US claimed
EP-3141552-A1 THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE Hanmi Pharm. Co., Ltd. (KR) 2017-03-15 EP claimed
EP-2528920-A2 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE Hanmi Pharm. Co., Ltd. (KR) 2012-12-05 EP claimed
US-20120302567-A1 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2012-11-29 US claimed
WO-2011093672-A2 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE HANMI PHARM. CO., LTD. (KR) 2011-08-04 WO claimed
EP-3141552-B1 THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE HANMI PHARM IND CO LTD (KR) 2019-04-17 EP disclosed
US-10112954-B2 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase HANMI PHARM. CO., LTD. (KR) 2018-10-30 US disclosed
EP-3141552-A1 THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE Hanmi Pharm. Co., Ltd. (KR) 2017-03-15 EP disclosed
EP-2528920-A2 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE Hanmi Pharm. Co., Ltd. (KR) 2012-12-05 EP disclosed
US-20120302567-A1 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2012-11-29 US disclosed
WO-2011093672-A2 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE HANMI PHARM. CO., LTD. (KR) 2011-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302567-A1 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE CDK2, SBK3, CDK2AP1 FGFR3 437/4885FGFR2 377/4885FGFR1 285/4885
US-10112954-B2 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase CDK2, SBK3, CDK2AP1 FGFR3 437/4885FGFR2 377/4885FGFR1 285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.